Crossmark

Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk

Crossref DOI link: https://doi.org/10.1007/s00439-016-1647-9

Published Online: 2016-03-05

Published Print: 2016-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tragante, Vinicius

Asselbergs, Folkert W.

Swerdlow, Daniel I.

Palmer, Tom M.

Moore, Jason H.

de Bakker, Paul I. W.

Keating, Brendan J.

Holmes, Michael V. https://orcid.org/0000-0001-6617-0879
Funding

Funding for this research was provided by:

Netherlands Heart Foundation (2014T001)

CVgenes@target (2014T001)
License Information

Text and Data Mining valid from 2016-03-05

Version of Record valid from 2016-03-05
More Information

Article History

Received: 29 October 2015

Accepted: 7 January 2016

First Online: 5 March 2016

Compliance with ethical standards

:

: FWA is supported by a Dekker scholarship-Junior Staff Member 2014T001—Netherlands Heart Foundation. The research leading to these results has received funding from the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement n° HEALTH-F2-2013-601456 (CVgenes-at-target).

: DIS is a consultant to Pfizer.

Document is current

Any future updates will be listed below